Monalizumab (Anti-Human CD159a)

Catalog No.A2053 Purity:99%

Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.

Click to purchase the isotype control of Monalizumab (Anti-Human CD159a)

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 7.72mg/ml Endotoxin Level: ＜1EU/mg

Choose Selective CD markers Inhibitors

Name	Citation	CD38	CD45	CD39	CD88	CD73	Others
RBN013209	0	++
MK-0159	0	+++
CD38 inhibitor 1 (compound 78c)	5	+++
AB680	0					++++
NQ301	1		+				TXA2 receptor
SodiuM Metatungstate	3			++
PMX-53				✔
LY-3475070					✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.

References
[1] Hwang M, et,al. J Clin Pharmacol. 2023 Jul;63(7):817-829.

References

[1] Hwang M, et,al. J Clin Pharmacol. 2023 Jul;63(7):817-829.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1228763-95-8
Molecular Weight	150 kDa
Isotype	Human IgG4-Kappa
Application	Monalizumab (Anti-Human CD159a)
Purification	Protein G
Sterility	0.2 μM filtered
Formulation	PBS Buffer, PH 7.4
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.